Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome

Department of Medicine, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, Puerto Rico.
Puerto Rico health sciences journal (Impact Factor: 0.67). 07/2004; 23(2):89-93.
Source: PubMed

ABSTRACT To compare effectiveness of oral therapy with reduced nicotinamide adenine dinucleotide (NADH) to conventional modalities of treatment in patients with chronic fatigue syndrome (CFS).
CFS is a potentially disabling condition of unknown etiology. Although its clinical presentation is associated to a myriad of symptoms, fatigue is a universal and essential finding for its diagnosis. No therapeutic regimen has proven effective for this condition.
A total of 31 patients fulfilling the Centers for Disease Control criteria for CFS, were randomly assigned to either NADH or nutritional supplements and psychological therapy for 24 months. A thorough medical history, physical examination and completion of a questionnaire on the severity of fatigue and other symptoms were performed each trimester of therapy. In addition, all of them underwent evaluation in terms of immunological parameters and viral antibody titers. Statistical analysis was applied to the demographic data, as well as to symptoms scores at baseline and at each trimester of therapy.
The twelve patients who received NADH had a dramatic and statistically significant reduction of the mean symptom score in the first trimester (p < 0.001). However, symptom scores in the subsequent trimesters of therapy were similar in both treatment groups. Elevated IgG and Ig E antibody levels were found in a significant number of patients.
Observed effectiveness of NADH over conventional treatment in the first trimester of the trial and the trend of improvement of that modality in the subsequent trimesters should be further assessed in a larger patient sample.

1 Follower
30 Reads
  • Source
    • "Twenty of the included trials adopted a two-arm parallel group design [10-12,14,15,17-27,29,30,33,35], three adopted a three-arm parallel group design [16,28,34], and one used a four-arm parallel group design [13], while two trials employed a cross-over design [31,32]. Nine trials adopted the CDC criteria for the diagnosis of CFS [11,20,22,24,25,27,28,31,32], five studies diagnosed CFS according to the criteria published by Fukuda [10,15,16,19,21], five used the Oxford criteria [12,17,18,30,35], two combined with Fukuda and Oxford criteria [13,23], and one used a different classification system [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Throughout the world, patients with chronic diseases/illnesses use complementary and alternative medicines (CAM). The use of CAM is also substantial among patients with diseases/illnesses of unknown aetiology. Chronic fatigue syndrome (CFS), also termed myalgic encephalomyelitis (ME), is no exception. Hence, a systematic review of randomised controlled trials of CAM treatments in patients with CFS/ME was undertaken to summarise the existing evidence from RCTs of CAM treatments in this patient population. Seventeen data sources were searched up to 13th August 2011. All randomised controlled trials (RCTs) of any type of CAM therapy used for treating CFS were included, with the exception of acupuncture and complex herbal medicines; studies were included regardless of blinding. Controlled clinical trials, uncontrolled observational studies, and case studies were excluded. A total of 26 RCTs, which included 3,273 participants, met our inclusion criteria. The CAM therapy from the RCTs included the following: mind-body medicine, distant healing, massage, tuina and tai chi, homeopathy, ginseng, and dietary supplementation. Studies of qigong, massage and tuina were demonstrated to have positive effects, whereas distant healing failed to do so. Compared with placebo, homeopathy also had insufficient evidence of symptom improvement in CFS. Seventeen studies tested supplements for CFS. Most of the supplements failed to show beneficial effects for CFS, with the exception of NADH and magnesium. The results of our systematic review provide limited evidence for the effectiveness of CAM therapy in relieving symptoms of CFS. However, we are not able to draw firm conclusions concerning CAM therapy for CFS due to the limited number of RCTs for each therapy, the small sample size of each study and the high risk of bias in these trials. Further rigorous RCTs that focus on promising CAM therapies are warranted.
    BMC Complementary and Alternative Medicine 10/2011; 11(1):87. DOI:10.1186/1472-6882-11-87 · 2.02 Impact Factor
  • Source
    • "Plant constituents that have been reported to be free radical scavengers and anti-lipoperoxidative include polyphenol (Maisuthisakul et al., 2007; Adedapo et al., 2009), reduced glutathione (Bhatia and Jain, 2004) and NADH (Stern et al., 2002). NADH therapy is known to have beneficial effects in patience with chronic fatigue syndrome (Santaella et al., 2004). Polyphenols have antioxidant and iron-chelating properties and can combat oxidative stress. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gunnera perpensa L. (Gunneraceae) is a medicinal plant used by Zulu traditional healers to induce labor, expel the placenta after birth and to relief menstrual pains. Phytochemical screening of the rhizomes revealed the presence of alkaloids, flavonoids, steroids, saponins, tannins and glycosides. Methanol extracts of G. perpensa exhibited strong scavenging of 2,2-Diphenyl-1-picryl-hydrazyl (DPPH) and 3-ethylbenzothiazoline-6-sulfonate (ABTS), but showed poor (< 50%) radical scavenging of nitric oxide, superoxide and hydroxyl radicals. At a concentration of 5 mg/100 ml, the extract was able to inhibit lipid peroxidation of the whole rat brain homogenate (71.13%) and lipoxygenase (30%) activity. The plant extract also contained reduced form of nicotinamide adenine dinucleotide (NADH, 3.8 m/g), total phenol (248.45 mg/g) and traces of sulfhydryl groups (SH). The total antioxidative capacity was 36% relative to ascorbic acid (AA) and 64% relative to butylated hydroxyl toluene (BHT). The cytotoxicity of the extract (LC 50) to brine shrimp larvae was 137.62 mg/ml. It is apparent that the antioxidant activity of G. perpensa contributes to its effectiveness in folk medicine.
  • Source
    • "Micronutrients are substances that are not synthesized in the body but have to be provided by food intake to maintain normal body functions. Micronutrients are known to resist fatigue and to have beneficial effects in the treatment of chronic fatigue syndrome (Forsyth et al., 1999; Logan et al., 2003; Dorman et al., 2004; Santaella et al., 2004). This study estimated the presence of NADH, polyphenols and sulfhydryl compounds in Trichopus zeylanicus. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic fatigue is considered a complex symptom for which currently there is no curative treatment available. Oxidative stress plays an important role in the etiology of fatigue and antioxidant treatment might be a valuable therapeutic approach. The Kani, a tribal high altitude living population in southern India, traditionally use the seeds of Trichopus zeylanicus to combat fatigue. In this study, the antioxidant properties of Trichopus zeylanicus were established on free radicals (DPPH and ABTS), its ability to reduce iron, lipoxygenase activity and hydrogen peroxide-induced lipid peroxidation. The effects of Trichopus zeylanicus on reactive oxygen species induced plasmid DNA (pBR322) cleavage were also investigated. Trichopus zeylanicus significantly scavenged free radicals, reduced lipid peroxidation and inhibited lipoxygenase activity. Trichopus zeylanicus also exhibited iron-chelating activity and inhibited reactive oxygen species induced DNA damage. Trichopus zeylanicus contains NADH, polyphenols and sulfhydryl compounds, which have the ability to scavenge reactive oxygen species suggesting that the antioxidant activity may be an important mechanism of action of Trichopus zeylanicus to combat fatigue.
    Phytotherapy Research 08/2005; 19(8):669-73. DOI:10.1002/ptr.1725 · 2.66 Impact Factor
Show more


30 Reads
Available from